Effects of the Synbiotic Formulation EDC-HHA01 on Glucose Regulation in Adults with Type 2 Diabetes and Prediabetes : A Randomized, Placebo-Controlled Study
Authors:
- Gissel GarcíaGGGissel García
- María del Carmen CamposMCMaría del Carmen Campos
- Josanne SotoJSJosanne Soto
- Antonio DiazADAntonio Diaz
- Emilio BuchacaEBEmilio Buchaca
- Duniesky MartínezDMDuniesky Martínez
- Mirka BernalMBMirka Bernal
- Viviana EscobarVEViviana Escobar
- Lais RodríguezLRLais Rodríguez
- Eduardo ValdésEVEduardo Valdés
- Maricela NuezMNMaricela Nuez
- Noraika DomínguezNDNoraika Domínguez
Preprint
- 5 January 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Microbiome-targeted interventions have shown promise for metabolic health, yet clinical evidence remains inconsistent, particularly across stages of metabolic disease. This study evaluated the metabolic effects, safety, and tolerability of EDC-HHA01, a microbiome-informed, non-pharmacologic intervention, in adults with prediabetes (PD) or Type 2 Diabetes (T2DM). Methods: In a randomized, double-blind, placebo-controlled clinical trial, participants received EDC-HHA01 or placebo for six months. The study was adequately powered (≥80%) for the primary endpoint. Outcomes included changes in glycated hemoglobin (HbA1c), indices of insulin resistance, markers of metabolic endotoxemia, safety-related laboratory parameters, and exploratory patient-reported measures. Analyses were stratified by metabolic status and background metformin use. Results: In participants with PD, EDC-HHA01 supplementation was associated with a statistically and clinically meaningful reduction in HbA1c compared with placebo, supported by concordant improvements in fasting insulin, insulin resistance indices, and reductions in endotoxemia markers. In participants with T2DM, changes were directionally similar but attenuated and did not reach statistical significance. The intervention was well tolerated, with no serious adverse events, high adherence, and no clinically relevant adverse changes in renal or lipid parameters. Exploratory patient-reported outcomes indicated favorable acceptability but were not interpreted as efficacy endpoints. Conclusions: EDC-HHA01 was associated with biologically coherent, stage-dependent metabolic effects, most evident in PD. These findings support further investigation of microbiome-informed strategies as metabolic support in early-stage dysregulation.Keywords
All Related Versions
- Version 1, 2026-01-05, Preprints
- Published version: Microorganisms, 14 (4), 749.
This publication has 73 references indexed in Scilit:
- Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic ContinuumCurrent Obesity Reports, 2025
- Advances in crosstalk among innate immune pathways activated by mitochondrial DNAHeliyon, 2024
- Early-life gut microbiota and its connection to metabolic health in children: Perspective on ecological drivers and need for quantitative approachEBioMedicine, 2021
- The Challenge of Reforming Nutritional Epidemiologic ResearchJAMA, 2018
- Modeling metabolism of the human gut microbiomeCurrent Opinion in Biotechnology, 2018
- Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 DiabetesJAMA, 2017
- Impaired fasting glucose and impaired glucose tolerance in children and adolescents with overweight/obesityJournal of Endocrinological Investigation, 2016
- Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in HumansCell, 2016
- CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trialsInternational Journal of Surgery, 2012
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985